A Contrarian Call: Why One Analyst Sees Value in Novo Nordisk’s Slump

Despite navigating a challenging period for its share price, Novo Nordisk has received a significant vote of confidence from research firm Kepler Cheuvreux. In a notable move, the analyst has designated the Danish pharmaceutical giant as its premier "Top Pick" within the sector. This endorsement comes even as the firm reduced its price target on the stock, highlighting a compelling divergence between market sentiment and perceived fundamental strength.

Kepler Cheuvreux reaffirmed its "Buy" rating on Novo Nordisk but adjusted its price target downward to 430 Danish Kroner from 510. This revision is attributed to broader industry reassessments and mounting pricing pressures affecting the pharmaceutical landscape.

The simultaneous elevation to "Top Pick" status, however, sends a powerful counter-signal. The analysts interpret the stock's severe decline in 2025—a period the source material describes as a "Year of Pain" with double-digit losses—as an overreaction relative to the company's earnings potential. From this perspective, the current valuation discount appears to reflect fears over regulatory and competitive risks more than any inherent business weakness.

This view is supported by valuation metrics. Based on 2026 estimates, the shares are trading at a forward price-to-earnings (P/E) ratio of approximately 12.7. This sits notably below the sector average of 17.6 and beneath the company's own valuation levels during the boom years of 2023 and 2024. The market, it seems, is pricing in a worst-case scenario for U.S. drug pricing and competitive dynamics. Kepler's call suggests this pessimism has created a potential opportunity.

The price action tells its own story: while the stock has gained 6.28% over the past week, it remains down more than 50% year-to-date and roughly 59% below its 52-week high from mid-December 2024.

Strategic Maneuvers: Wegovy's High-Dose Play and Global Expansion

Operationally, the focus remains sharply on the obesity drug Wegovy. Novo Nordisk recently submitted an application to the U.S. FDA for a high-dose 7.2 mg version. Cited study data indicates this formulation could achieve an average weight loss of 20.7%, a significant improvement over the approximately 15% associated with the standard dose.

This potential label expansion is a central pillar of the strategy to counter the competitive threat from Eli Lilly's rival therapy, Zepbound. Superior efficacy data on the product label offers a clear advantage in the battle for physician prescriptions and patient adoption, particularly in a market heavily influenced by clinical results and regulatory wording.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Alongside this, Novo Nordisk is aggressively pursuing international growth. Its diabetes medication Ozempic was launched in India on December 12, priced at a weekly level of around $24. This competitive pricing aims to capture volume in the vast Asian market, a move designed to help offset potential margin compression in more established regions.

Navigating a Landscape of Uncertainty

Kepler's reassessment arrives during a phase of heightened investor anxiety. Throughout 2025, Novo Nordisk shares have faced pressure from a confluence of factors:

• Concerns regarding an approaching "patent cliff" in the coming years.
• Intensifying political scrutiny and pressure on drug pricing, particularly in the United States.
• Significant sentiment volatility affecting the entire obesity drug sector.

U.S. political rhetoric has weighed heavily. Recent comments from former President Donald Trump regarding potential price caps for obesity medications—such as limiting Ozempic to $150—have amplified market nervousness and contributed to a tangible valuation discount in the current quarter.

The competitive environment also grows more intense, with new entrants like Structure Therapeutics reporting progress on oral GLP-1 candidates. Nevertheless, the source emphasizes that Novo Nordisk's established market position and massively expanded production capacity—bolstered by substantial investments in 2025—provide a considerable moat. This scale and supply capability represent a defensive barrier that smaller challengers are unlikely to overcome in the near term.

The Road Ahead: Regulatory Milestones and Pipeline Catalysts

The immediate spotlight falls on an anticipated FDA decision within the next one to two months regarding an accelerated review for the 7.2 mg Wegovy formulation. A swift and positive outcome would bolster the lifecycle management strategy for semaglutid and reinforce the long-term earnings argument made by Kepler's analysts.

Looking to 2026, consensus estimates point to a stabilization. Revenue growth is expected to steady, with higher sales volumes partially offsetting anticipated pricing concessions. From a technical standpoint, the question is whether current price levels can form a sustainable base, potentially supported by the new "Top Pick" rating and the significantly de-risked valuation.

Strategically, the pipeline candidate Amycretin remains crucial. This dual-acting successor to Wegovy is viewed as the key to maintaining Novo Nordisk's effective duopoly with Eli Lilly into the late 2020s. Progress in this development program will likely determine whether the current valuation discount evolves into a new growth narrative or becomes entrenched at lower levels.